D-Bal MAX is a revolutionary new muscle-building supplement that will put you on the fast track to building lean muscle and ...

Tallmadge, Ohio, May 01, 2025 (GLOBE NEWSWIRE) -- Following Over 90 Days of Personal Experience, Here’s What Truly Occurred ...

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results ...

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), today announced that it plans to submit a Q-Submission (“Q-Sub”) to the U.S. Food and Drug Administration (FDA) related to ...

CORAnet® Solutions facilitates interoperability across networks and platforms, giving patients and their families ownership and personal control of their medical records. Our advanced software ensures ...

HNL Lab Medicine invites local artists in grades K–8 to enter its Annual Art Contest by May 31, 2025, for a chance to win a one-year membership to the Da Vinci Science Center or Crayola Experience and ...

The Company’s Class A Ordinary Shares will begin trading on the Nasdaq Global Market on a post-Reverse Stock Split basis under the current ticker symbol “NIVF” at the commencement of trading on May 5, ...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ®  platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that Nicole Davarpanah, ...

Following a review process conducted with the assistance of its legal and financial advisors, the Kronos Bio Board of Directors has determined that the acquisition by Concentra is in the best ...

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on ...

Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their JMP, ...

The Company’s new corporate strategy seeks to acquire assets that contribute revenue including the acquisition of small biotech companies with FDA approved products. Windtree will continue to develop ...